Orderingång accelererade till en ny nivå - igen... Med bred, fortsatt återhämtning i efterfrågan väx...
Förbättrat resultat i säsongsmässigt svagt första kvartal Bokusgruppen fortsatte på den inslagna väg...
Stark rapport Hyresintäkterna i kvartalet uppgick till 1 831 mkr vs marknadens estimat om 1 771 mkr.
Vaisala’s Q1 result topped our expectations clearly.
Exel’s Q1 report showed the company is making progress in the US as the unit was back to black.
Amhult 2 publicerade den 27 april resultatet för det första kvartalet 2022 och vi är mycket nöjda öv...
Redeye is optimistic about PulmoStem in lung transplantation following positive results in a preclin...
För S2Medical har pandemin satt käppar i hjulet för dess framfart.
Main points in SRV’s Q1 report related to the write-downs of holdings relating to Russia and Fennovo...
Solteq’s Q1 figures were well in line with expectations.
Redeye has a positive view of Orexo after the Q1 report, but we see a challenge to stabilising the Z...
BankNordik reported solid Q1 2022 figures across all income lines, and underlying profitability came...
Redeye bibehåller BioArctics värdering på 250 kronor per aktie efter rapporten.
CapMan reported a strong Q1 with high fair value changes despite writedowns related to old Russian i...
Redeye sees a solid Q1 report from Sdiptech on the group level.
Redeye lowers its fair value range after a weak Q1 report.
Redeye comments on Medivir’s first quarter report.
Sales -1% vs cons and EBIT -81% vs. cons Supply chain - the main explanation of the low profitabilit...
Redeye changes our short-term estimates on the back of a challenging environment for Tagmaster.
Sales above CTT guidance and ABGSCe (+13%) Q2 mid-point guidance also 4% above ABGSCe Strong report ...
